CRISPR-Edited Dual Stem Cell Therapy Offers Fresh...
Aug. 14, 2023
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
AMASA Therapeutics
Company Type: Therapeutics
Main focus: High-grade glioblastoma (GBM)
Company stage: Pre-clinical
Diseases: Diverse cancers
Genome-editing tool: CRISPR-Cas9
Funding stage: Pre-seed
Location: Boston, USA
Website: https://www.amasatx.com/
Pipeline:
Partners:
AMASA Therapeutics is an early-stage biopharmaceutical company focused on the development of novel stem cell-based targeted biological therapies to treat cancer patients with unmet need. The company's platform technology includes encapsulated engineered allogeneic receptor-targeted cell-based therapeutics, and a proprietary procedure developed by the focal cancer therapy pioneer and inventor, Khalid Shah, MS, PhD., Professor at Harvard Medical School and Vice Chairman of Research at BWH-Neurosurgery.
